[Heterozygosity for alpha1-antitrypsin deficiency as a cofactor in the development of chronic liver disease]

Area of Science:

• Hepatology
• Genetics
• Pulmonology

Background:

• Alpha1-antitrypsin (AT) deficiency is a genetic disorder linked to liver cirrhosis and pulmonary emphysema.
• Heterozygous AT deficiency may contribute to chronic liver disease, even with normal serum AT levels, particularly alongside other risk factors like alcohol abuse or viral hepatitis.
• Individuals with AT deficiency mutations face increased risks for cryptogenic cirrhosis and primary liver-cell carcinoma.

Observation:

• Three patients (two men, one woman) with alcohol-related liver dysfunction experienced rapid deterioration and death.
• All three patients were found to be heterozygous for alpha1-antitrypsin (AT) deficiency.
• This suggests a potential link between heterozygous AT deficiency and severe, rapidly progressing liver disease.

Findings:

• Heterozygous alpha1-antitrypsin (AT) deficiency can exacerbate liver disease, leading to rapid deterioration and mortality, especially in individuals with co-existing risk factors such as alcohol abuse.
• Even normal serum alpha1-antitrypsin (AT) levels do not exclude the risk associated with heterozygous deficiency in the context of chronic liver disease.
• The study highlights a potential underestimation of risk in patients with chronic liver conditions and heterozygous AT deficiency.

Implications:

• Routine alpha1-antitrypsin (AT) phenotyping should be considered for patients with chronic liver disease, particularly those with unexpectedly rapid disease progression or normal AT serum levels.
• Early identification of heterozygous alpha1-antitrypsin (AT) deficiency can inform risk stratification and management strategies for liver disease.
• Liver biopsy remains essential for confirming alpha1-antitrypsin (AT) deposits in the liver, aiding diagnosis and understanding disease pathogenesis.